Cognition Therapeutics, Inc. has successfully enrolled 540 participants in the Phase 2 ‘START’ Study evaluating zervimesine for mild cognitive impairment and early Alzheimer’s disease. Results are expected after 18 months of treatment, with strong enrollment attributed to investigator interest. The study allows participants on approved monoclonal antibody therapy, with 15% also receiving Leqembi or Kisunla infusions. Zervimesine’s unique mechanism offers potential benefits for a broader range of Alzheimer’s patients, aiming to reduce disease progression. The study is supported by an $81 million grant from the National Institute of Aging.

Zervimesine (CT1812) is an oral, once-daily pill in development for Alzheimer’s disease and dementia with Lewy bodies, targeting the buildup of harmful proteins in the brain. The USAN Council has adopted zervimesine as the United States Adopted Name. Cognition Therapeutics, Inc. is focused on developing innovative therapies for degenerative CNS disorders, with zervimesine showing promise in ongoing Phase 2 studies. The company aims to regulate impaired pathways through interaction with the sigma-2 receptor.

Read more at GlobeNewswire: Cognition Therapeutics Completes Enrollment in Phase 2